Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 7/20 | 0.40 |
| ▸ | DCUN1D1 | Q96GG9 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 7/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2796900 | 0.92 | UBE2M (0.36) | UBE2MDCUN1D1LMNATSHRTHRB | |
| SCHEMBL2798160 | 0.90 | UBE2M (0.35) | UBE2MDCUN1D1LMNATSHRTHRB | |
| SCHEMBL2800601 | 0.90 | LMNA (0.40) | UBE2MDCUN1D1LMNATSHRTHRB | |
| SCHEMBL2800492 | 0.90 | KCNH2 (0.46) | UBE2MDCUN1D1LMNATSHRALDH1A1 | |
| SCHEMBL2797191 | 0.88 | UBE2M (0.38) | UBE2MDCUN1D1LMNATSHRTHRB | |
| SCHEMBL2800189 | 0.88 | UBE2M (0.38) | UBE2MDCUN1D1LMNATSHRTHRB | |
| SCHEMBL2795743 | 0.88 | UBE2M (0.39) | UBE2MDCUN1D1LMNATSHRTHRB | |
| SCHEMBL2800083 | 0.88 | GAA (0.34) | UBE2MDCUN1D1LMNATSHRALDH1A1 | |
| SCHEMBL2797333 | 0.87 | UBE2M (0.38) | UBE2MDCUN1D1LMNATSHRTHRB | |
| SCHEMBL2796346 | 0.87 | LMNA (0.40) | UBE2MDCUN1D1LMNATSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | UBE2M 2433/4885DCUN1D1 1317/4885LMNA 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.